Wicell Research Institute Inc
WiCell Research Institute
391972235
1999
Madison, WI 53719 United States
wicell.org
WiCellResearch
WiCell-209962172383492
WiCell Research Institute
WiCell Research Institute is a nonprofit organization dedicated to advancing stem cell technologies. Established in 1999, it serves as a supporting organization of the University of Wisconsin–Madison, contributing significantly to the field of human pluripotent stem cell research.
Mission and Activities
WiCell's mission is to provide high-quality stem cell lines and characterization services, aiming to advance regenerative medicine and cell and gene therapy globally. The organization offers a diverse range of human pluripotent stem cell lines, including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), disease models, genetically modified variants, and cGMP grade cell lines. Its services include cell banking, characterization testing, and distribution of stem cell lines, as well as quality control testing and long-term liquid nitrogen storage solutions[1][3].
History and Achievements
In its early years, WiCell played a pivotal role in hosting the National Stem Cell Bank, which collected, banked, characterized, and distributed the 21 human embryonic stem cell lines approved for federal funding in the U.S.[1]. The institute has also provided training to over 800 scientists worldwide and has licensed human embryonic stem cell lines to more than 500 researchers across 32 countries and 42 states[2].
Services and Impact
WiCell's Stem Cell Bank is renowned for its comprehensive collection of cell lines submitted by researchers globally. The bank supports both academic and commercial research, offering characterization services such as karyotyping, fluorescence in situ hybridization (FISH), microarray analysis, and mycoplasma testing[1][3]. WiCell collaborates with other entities to facilitate the distribution of extensively characterized cell lines, enhancing the availability of NIH-eligible lines for U.S. researchers[2].
Partnership and Recognition
WiCell has collaborated with entities like Cellartis AB to deposit cell lines with the U.S. National Stem Cell Bank, furthering the accessibility of highly characterized human embryonic stem cell lines[2]. The institute is recognized for its commitment to quality and innovation, supporting groundbreaking research and clinical applications[3].
[1] https://www.wicell.org/home/about-us/about-wicell.cmsx [2] https://www.wicell.org/1-12-09.cmsx [3] http://www.wicell.org [4] https://www.wicell.org [5] https://www.wicell.org/home/stem-cells/stem-cells.cmsx
Podobné organizace
Podobné organizace global
THE UK STEM CELL FOUNDATION |
|
CELL FOUNDATION |
|
NSW Stem Cell Network |
|
The Trustee For A Cure Foundation |
|
Australasian Society For Stem Cell Research Inc |
Novinky
The wait is almost over! #ISSCR2025 begins tomorrow in Hong Kong, and WiCell is proud to be a bronze sponsor. Dr. Tenneille Ludwig, Director of WiCell’s Stem Cell Bank, will be attending and participating in sessions throughout the week. If you're looking to connect and discuss how WiCell's cGMP and research grade testing and our diverse collection of over 1500 stem cell lines can help you in your research and path to the clinic, be sure to reach out through the partnering portal to meet with her. We hope to see you there! #WiCell #ISSCR2025 #YourLabPartner (fb)
We’re excited to share that Dr. Tenneille Ludwig, Director of WiCell’s Stem Cell Bank, will be actively participating in multiple sessions at #ISSCR2025. If you are in Hong Kong, make sure you put these sessions on your schedule! Clinical Trial Updates 📅 June 11 | 🕗 8:30–10:00 AM HKT | 📍 Theater 1, L1 Serving as Co-Chair, Dr. Ludwig will oversee discussions on the latest clinical breakthroughs from pivotal stem cell-based therapy trials. Best Practices for the Translation of Pluripotent Stem Cell-Derived Therapies 📅 June 12 | 🕗 8:30–10:00 AM HKT | 📍 Hall 3G, L3 Dr. Ludwig will be speaking in this session, focusing on the tools and technologies advancing the safety of iPSC- and ESC-derived products. Manufacturing with Commercialization in Mind 📅 June 13 | 🕗 8:30–10:00 AM HKT | 📍 Hall 3G, L3 Dr. Ludwig will be speaking in this session, addressing strategies to bridge the gap between manufacturing processes and commercial application in stem cell therapies. (fb)
Poslední komentáře
Incredible work, WiCell! Your commitment to advancing stem cell research is truly inspiring. Keep paving the way for scientific breakthroughs! 🌟detail |
|
Congratulations on the well-deserved recognition, Dr. Tenneille Ludwig! It's amazing to see such dedication in enhancing our understanding of stem cells. Here's to many more discoveries! 👏✨detail |
Poslední diskuze
1. How can collaborations between organizations like WiCell and pharmaceutical companies enhance the development of iPSC-derived therapies?Odpovědí: 3, Naposledy před 1 den detail |
|
2. What ethical considerations should be addressed in the banking and distribution of human pluripotent stem cells for research purposes?Odpovědí: 3, Naposledy před 1 den detail |
V okolí
50
4.5
Madison
O společnosti
- H11 -
Safeguard your research Discover more about WiCellSAFE cGMP FISH and Karyotype Affordable accurate testing from the stem cell experts Over 1500 cell lines hESCs iPSCs diverse disease models WICELLA RECOGNIZED WORLD LEADER IN STEM CELL SCIENCE Fate Therapeutics has worked with WiCell over the past decade. WiCell has characterized cell lines for Fate and they have delivered high quality study results as well as outstanding and knowledgeable service and technical support. WiCell has supported both our research and translational studies including in support of IND clearance of our iPSCderived cell products. ISSCR Names Dr.
Podpora jediné organizace
